Abstract Number: 1716 • ACR Convergence 2020
Predictors of Unacceptable Pain and Unacceptable Pain with Low Inflammation in Early Rheumatoid Arthritis
Background/Purpose: Pain is a common and debilitating symptom in patients with rheumatoid arthritis (RA). In early RA it is usually due to ongoing inflammation and…Abstract Number: 1732 • ACR Convergence 2020
Machine Learning Coupled with Patient Reported Outcome Data to Classify & Predict RA Disease Activity
Background/Purpose: Patient reported outcome (PRO) data have assumed increasing importance in the care of rheumatoid arthritis (RA) patients. However, physician-derived disease activity measures such as…Abstract Number: 1749 • ACR Convergence 2020
Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis
Background/Purpose: Patients (pts) with rheumatoid arthritis (RA) with poor prognostic factors (PPF) are at risk for RA progression if disease activity is not rapidly controlled.…Abstract Number: 1773 • ACR Convergence 2020
Worse Maternal and Fetal Outcomes Among Hospitalized U.S. Pregnant Women with Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)
Background/Purpose: Prior studies suggest women with SLE and RA may have higher age-adjusted risk of adverse pregnancy outcomes. We evaluated maternal and fetal complications and…Abstract Number: 1981 • ACR Convergence 2020
Patients with Inflammatory Arthritis Who Are More Adherent to Treatment Do Not Perform More Physical Activity Collected by Smartphone Apps: A Cross-sectional Study of 101 Patients, the ImBAIA Study
Background/Purpose: Adherence to both medications and physical activity is insufficient in patients with inflammatory arthritis (IA), such as spondyloarthritis (axSpA), rheumatoid arthritis (RA) or psoriatic…Abstract Number: 2009 • ACR Convergence 2020
Treat-to Target for Early RA Patients in Usual Clinical Practice, a Randomized Study with a Favorable Effect of a Second Oral Pulse of Prednisolone. the Amsterdam COBRA Treat-to-target Study
Background/Purpose: EULAR guidelines advise to start with methotrexate (MTX) for early rheumatoid arthritis (RA), either alone or combined with prednisolone. Since this strategy is not…Abstract Number: 0033 • ACR Convergence 2020
Pre-pregnancy Long Non-coding RNA Expression Signatures Among Women with Rheumatoid Arthritis Who Improve or Worsen During Pregnancy
Background/Purpose: Pregnancy is known to have disease-modifying effects on rheumatoid arthritis (RA). A role for long non-coding (lnc) RNAs in the improvement or worsening of…Abstract Number: 0105 • ACR Convergence 2020
Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients
Background/Purpose: Rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have both been associated with generalized and localized bone loss. Inflammatory cytokines like tumor necrosis factor (TNF)…Abstract Number: 0152 • ACR Convergence 2020
Veterans with RA and Gout Identify Their Goals and How They Can Work with Clinicians to Achieve Their Goals
Background/Purpose: Understanding patient goals and concerns is essential for aligning treatment decisions with patient preferences and supporting effective patient-clinician partnerships. Yet, little is known about…Abstract Number: 0187 • ACR Convergence 2020
Regional and Widespread Patterns of Non-articular Pain Are Common at RA Diagnosis and Contribute to Poor Outcomes at 12 Months: A Prospective Study of Pain Patterns in Canadians with RA
Background/Purpose: Persistent pain can occur in early RA patients, despite improvement in synovitis and may be due to coexisting non-articular pain (NAP). Though NAP is…Abstract Number: 0203 • ACR Convergence 2020
Safety of Baricitinib in Patients with Rheumatoid Arthritis: Interim Report from All-Case Post‑Marketing Study in Clinical Use
Background/Purpose: To evaluate the safety of baricitinib in rheumatoid arthritis (RA) patients in clinical use.Methods: An all-case post-marketing study of baricitinib, started in September 2017,…Abstract Number: 0219 • ACR Convergence 2020
Is It Realistic to Stop Prednisone in Early Rheumatoid Arthritis? A Subanalysis from the BeSt and IMPROVED Studies
Background/Purpose: Glucocorticoids are widely used in the treatment of rheumatoid arthritis (RA) patients. It is internationally recommended to taper and stop glucocorticoids as rapidly as…Abstract Number: 0236 • ACR Convergence 2020
Safety and Usability of Infliximab Administration by Auto-injector (AI) and Pre-filled Syringe (PFS) in Patients with Active Rheumatoid Arthritis (RA): Patient-reported Experience from a Multicenter, Randomized Controlled Pivotal Trial
Background/Purpose: The subcutaneous (SC) formulation of CT-P13 received marketing authorization for RA from the EMA by demonstrating non-inferiority compared to CT-P13 intravenous for efficacy in…Abstract Number: 0480 • ACR Convergence 2020
Impact of Targeting Remission or Low Disease Activity on 10-year Severity in Rheumatoid Arthritis : Data from ESPOIR Cohort
Background/Purpose: The aim of rheumatoid arthritis (RA) treatment is to target remission or at least low disease activity (LDA). We previously showed that SDAI remission…Abstract Number: 0567 • ACR Convergence 2020
Rheumatologist’s Perception of the Efficacy, Safety and Willingness to Prescribe Infliximab and Use Alternate Drug Supply Programs to Lower Cost of Rheumatoid Arthritis Care
Background/Purpose: There is interest in employing biosimilar therapies for patients with rheumatoid arthritis (RA), which have been shown comparable to originator biologics in safety and…
- « Previous Page
- 1
- …
- 156
- 157
- 158
- 159
- 160
- …
- 188
- Next Page »